【摘要】 目的观察恩度(重组人血管内皮抑素,YH-16)联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌的近期临床疗效,评价恩度临床应用的安全性和耐受性。方法 GP+YH-16(治疗组)和GP(对照组)方案化疗两周期。结果治疗组客观有效率为45.5%,疾病控制率为90.9%,症状缓解率为81.8%,生活质量改善率为63.6%;对照组分别为34.3%,71.4%,60.0%,40.0%;除客观有效率比较差异无统计学意义外(P>0.05),其余指标比较差异均有统计学意义(P<0.05)。不良反应多数是1/2级,主要与化疗有关,治疗组出现4例心悸和心率失常。结论恩度与GP方案联合应用,能提高晚期NSCLC的疾病控制率,能在一定程度上缓解弥漫性肺小结节转移灶和浆膜腔积液,从而改善肺功能和生活质量,且安全性较好。更多还原

【Abstract】 Objective To investigate the short-term efficacy and toxicity of YH-16 combined with GP regimen for NSCLC.Methods The patients were divided into GP + YH-16(trial group) and GP(control group),and the efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria.Results The trial group’s effective rate was 45.5% while the control group was 34.3%,P>0.05.For three other results:the disease control rate symptomatic relief rate and QOL improvement rate,they were 90.9%,81.8% and 63.6% in the trial group and 71.4%,60.0% and 40.0% in the control group respectively,P<0.05.Side effects were almostly grade 1/2 and concened with chemotherapy.4 patients in the trial group suffered cardiopalmus and arrhythmias.Conclusion The combination of YH-16 with GP regimen could improve the disease control rate of advanced NSCLC obviously,relieving metastasis focus of tumor,reducing the serous pleural effusion,improving lung function.Besides,side effects was less than those of others.更多还原